A New Preventive Tool for Genetic Risk

For years, receiving a positive genetic test for cardiomyopathy felt like a dead end. Patients were told they were at high risk for heart failure, but doctors had few, if any, preventive therapies to offer. That clinical stalemate may be shifting. A new analysis published in Nature Medicine suggests that dapagliflozin, a common type 2 diabetes medication, could slash the risk of heart failure hospitalization by roughly 80% in people carrying specific cardiomyopathy-associated genetic variants.

Researchers from the Mass General Brigham Heart and Vascular Institute and the Broad Institute of MIT and Harvard analyzed data from the DECLARE-TIMI 58 trial, a large-scale Phase III study. They focused on 121 participants who carried pathogenic or likely pathogenic variants in high-confidence cardiomyopathy genes. The results suggest that these genetic markers could serve as a roadmap for targeted, preventive treatment.

The Data Behind the Shift

In the study, variant carriers who received a placebo faced an eightfold increased risk of heart failure hospitalization compared to the general study population. Over a median follow-up of 4.2 years, 16% of those placebo-treated carriers were hospitalized for heart failure. Among those who received dapagliflozin, that figure plummeted to 3%.

Perhaps most striking was the benefit observed in patients who had not yet developed heart failure. Roughly 82% of the variant carriers in the study were asymptomatic at the time of enrollment. In this group, dapagliflozin reduced the absolute risk of heart failure hospitalization by 12.8%, a significantly larger impact than the 0.6% reduction seen in non-carriers.

“Historically, identifying a genetic variant for cardiomyopathy mostly meant telling a patient they were at high risk and not having a specific preventative therapy to offer,” said co-lead author Shinwan Kany, MD, a visiting scientist at the Cardiovascular Research Center. “These data show we do have tools to lower risk in these individuals.”

Why Context Matters

While the findings are promising, they come with important caveats. This was a post-hoc analysis, meaning the study was not originally designed to test this specific hypothesis. Furthermore, the number of variant carriers identified within the trial was relatively small, and all participants had type 2 diabetes and elevated cardiovascular risk.

Because of these factors, it remains unclear whether the same degree of protection would extend to individuals without diabetes. The researchers emphasize that these results should not be viewed as a universal prescription but rather as a foundation for future prospective clinical trials. These upcoming studies will be designed specifically to evaluate whether dapagliflozin or similar SGLT2 inhibitors can serve as a primary preventive strategy for healthy carriers of cardiomyopathy genes.

Key Takeaways

  • Dapagliflozin, an SGLT2 inhibitor, was associated with an 82% relative reduction in heart failure hospitalization among carriers of cardiomyopathy-associated genetic variants.
  • The most significant benefits were observed in patients who had not yet developed heart failure, suggesting the drug could act as a powerful preventive intervention.
  • The study was a post-hoc analysis of a diabetes trial, meaning further prospective research is required to confirm these benefits in non-diabetic populations.

What Experts Say

Co-lead author Nicholas A. Marston, PhD, a cardiologist at Brigham and Women’s Hospital, noted that these findings could change how clinicians approach genetic screening. “Cardiomyopathy variants represent an actionable genotype which can be used to identify patients who derive a larger benefit from dapagliflozin,” Marston said. “This is especially relevant for patients without established heart failure, where such treatment may not be otherwise initiated.”

As the medical community awaits the launch of prospective trials, the next critical decision point for clinicians will be whether to incorporate genetic screening more aggressively into the management of patients with early-stage cardiovascular risk. If future trials replicate these findings, the current standard of "watchful waiting" for asymptomatic gene carriers may soon be replaced by early pharmacological intervention.